| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th September 2020 | Steven W Lefkowitz | 2,215 | Open or private purchase | $3.98 | $8,815.70 |
| 4th September 2020 | Steven W Lefkowitz | 3,500 | Open or private purchase | $4.00 | $14,000.00 |
| 3rd September 2020 | Matthew T David | 1,150 | Open or private purchase | $4.07 | $4,680.50 |
| 2nd September 2020 | Myron Kaplan | 15,300 | Open or private purchase | $4.27 | $65,358.54 |
| 19th August 2020 | Mehmood Khan | 9,404 | Open or private purchase | $4.91 | $46,176.46 |
| 19th August 2020 | Mehmood Khan | 8,433 | Open or private purchase | $4.90 | $41,295.56 |
| 18th August 2020 | Mehmood Khan | 21,082 | Open or private purchase | $4.86 | $102,365.76 |
| 18th August 2020 | Mehmood Khan | 4,500 | Open or private purchase | $4.62 | $20,790.00 |
| 18th August 2020 | Mehmood Khan | 2,331 | Open or private purchase | $4.60 | $10,722.60 |
| 14th August 2020 | Jr. John L. Armstrong | 10,000 | Open or private purchase | $4.16 | $41,600.00 |
Cor Medix
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution.
Ticker: CRMD
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1410098
Employees: 22
Exchange: NYSE American
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $16 M (0%)
Inventory, Net: $278 Th (0%)
Assets, Current: $24 M (-17%)
Property, Plant and Equipment, Net: $103 Th (-18%)
Assets: $24 M (-17%)
Accounts Payable, Current: $1 M (35%)
Accrued Liabilities, Current: $4 M (0%)
Liabilities, Current: $6 M (-1%)
Liabilities: $6 M (-1%)
Common Stock, Value, Issued: $26 Th (1%)
Common Stock, Shares, Issued: $26 M (1%)
Retained Earnings (Accumulated Deficit): $205 M (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $106 Th (8%)
Stockholders' Equity (Parent): $19 M (0%)
Liabilities and Equity: $24 M (-17%)
Gross Margin: $3 Th (-87%)
Research and Development: $6 M (-30%)
Operating Income/Loss: $9 M (-38%)
Provision for income taxes: $5 M (0%)
News
CorMedix: Patent Coverage Is A Problem
13th November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020